Neurological Biomarkers Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Neurological biomarkers are measurable biological indicators used to detect, track, and predict the progression of neurological disorders and traumatic brain injuries. The market encompasses genomic, proteomic, metabolomic, and imaging-based biomarkers that support clinical decision-making and drug development pipelines. With a current valuation of $9.4 billion in 2025, the sector is positioned as a critical component of modern neuroscience and personalized healthcare strategies.

• •Spans diagnostic tests, research tools, and companion diagnostics for brain-related conditions
• •Incorporates liquid biopsies, neuroimaging agents, and genetic sequencing platforms
• •Serves hospitals, diagnostic labs, pharmaceutical companies, and research institutions

The aging global population is increasing the incidence of neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS, creating urgent demand for early and accurate diagnostic tools. Advances in genomics, mass spectrometry, and artificial intelligence are enabling the discovery of new biomarkers with greater specificity for neurological conditions. Growing investment in central nervous system drug development by pharmaceutical companies is further fueling demand, as validated biomarkers are essential for clinical trial enrollment and regulatory approval processes.

• •Over 55 million people worldwide live with dementia, with numbers projected to triple by 2050
• •AI-powered analysis of multi-omic datasets is accelerating biomarker discovery timelines
• •Regulatory agencies increasingly accept biomarker-based endpoints in CNS drug approvals

The market is broadly segmented by biomarker type, application, and end-use sector, with genomic and proteomic biomarkers currently dominating clinical and research adoption. Key applications include diagnostics, drug discovery and development, and personalized medicine, while end users span hospitals, diagnostic laboratories, and contract research organizations. Geographically, North America leads market share due to advanced healthcare infrastructure and strong R&D funding, while Europe and the Asia-Pacific region are expanding rapidly as neurological care access improves.

• •Genomic, proteomic, metabolomic, and imaging biomarkers each address different stages of disease management
• •North America accounts for the largest regional share, with Asia-Pacific expected to show the fastest growth rate
• •Diagnostics and drug development represent the two primary application segments

What are the recent trends and outlook?

Integration of artificial intelligence with multi-modal biomarker data is emerging as a transformative trend, enabling earlier detection of diseases before clinical symptoms manifest. Blood-based biomarkers for Alzheimer's disease, such as phosphorylated tau assays, have gained regulatory attention and are moving toward routine clinical use. The market's trajectory toward 2034 reflects sustained innovation, increasing partnerships between diagnostics firms and pharmaceutical companies, and expanding reimbursement pathways that should broaden access to biomarker testing worldwide.

• •Liquid biopsy and blood-based tau and amyloid biomarkers are shifting Alzheimer's diagnostics away from invasive procedures
• •AI and machine learning are improving the predictive accuracy of combined biomarker panels
• •Collaborations between diagnostics companies and biopharma firms are accelerating biomarker qualification for clinical trials